CDMO Market Heats Up With M&A, New Launch
The CDMO sector is seeing a flurry of activity as Fagron completed its acquisition of Vepakum to expand its custom manufacturing footprint. Meanwhile, a new competitor, Forma Life Sciences, has launched in California, focusing on digitally-enabled oral solid dosage manufacturing.
Consolidation in the highly fragmented CDMO sector is accelerating, with M&A activity poised for a rebound in 2026. Key drivers include the need to acquire specialized capabilities for complex biologics, expand geographically, and enhance supply chain resilience, with private equity playing an increasingly significant role in financing these deals. Fagron's acquisition of Vepakum, a packaging manufacturer with two facilities in São Paulo, Brazil, is part of a broader global expansion and vertical integration strategy. The deal was announced alongside the purchase of Amber Compounding Pharmacy in Singapore and Malaysia, with a combined price of approximately €55 million for the two businesses. The new entrant, Forma Life Sciences, was established after private equity firm BioSelective Capital Investments acquired the US manufacturing operations of BioDuro. Forma is led by former BioDuro CEO Cyrus K. Mirsaidi and operates two GMP facilities in Irvine, California, with an annual production capacity of over two billion tablets and capsules. Forma's focus on digital capabilities aligns with the broader Pharma 4.0 trend transforming manufacturing. This industry-wide shift leverages AI, IoT, and data analytics to create connected ecosystems, aiming to slash batch release times, reduce manual errors, and improve data integrity for GMP compliance. While oral solid dose remains a key market, the most intense CDMO growth and M&A is driven by demand for complex modalities like cell and gene therapies, mRNA, and antibody-drug conjugates. These advanced therapies present significant manufacturing challenges, including issues with scalability, high costs, and process robustness, which CDMOs are racing to solve. This push requires a sophisticated digital backbone, including advanced analytics, LIMS, and electronic batch records to manage process complexity and ensure quality. AI and machine learning are becoming central to process development, used for predictive modeling of bioprocesses, optimizing cell culture conditions, and accelerating the development of biologics. The biotech funding environment that underpins this activity remains one of cautious optimism after a volatile 2025. Investors are prioritizing companies with strong clinical data and de-risked assets, making the landscape more competitive but also driving big pharma to seek partnerships for cutting-edge innovation.
